Neoadjuvant chemotherapy in patients undergoing colonic resection for locally advanced nonmetastatic colon cancer: A nationwide propensity score matched cohort study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Neoadjuvant chemotherapy in patients undergoing colonic resection for locally advanced nonmetastatic colon cancer : A nationwide propensity score matched cohort study. / Laursen, Magnus; Dohrn, Niclas; Gögenur, Ismail; Klein, Mads Falk.

I: Colorectal Disease, Bind 24, Nr. 8, 2022, s. 954-964.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Laursen, M, Dohrn, N, Gögenur, I & Klein, MF 2022, 'Neoadjuvant chemotherapy in patients undergoing colonic resection for locally advanced nonmetastatic colon cancer: A nationwide propensity score matched cohort study', Colorectal Disease, bind 24, nr. 8, s. 954-964. https://doi.org/10.1111/codi.16116

APA

Laursen, M., Dohrn, N., Gögenur, I., & Klein, M. F. (2022). Neoadjuvant chemotherapy in patients undergoing colonic resection for locally advanced nonmetastatic colon cancer: A nationwide propensity score matched cohort study. Colorectal Disease, 24(8), 954-964. https://doi.org/10.1111/codi.16116

Vancouver

Laursen M, Dohrn N, Gögenur I, Klein MF. Neoadjuvant chemotherapy in patients undergoing colonic resection for locally advanced nonmetastatic colon cancer: A nationwide propensity score matched cohort study. Colorectal Disease. 2022;24(8):954-964. https://doi.org/10.1111/codi.16116

Author

Laursen, Magnus ; Dohrn, Niclas ; Gögenur, Ismail ; Klein, Mads Falk. / Neoadjuvant chemotherapy in patients undergoing colonic resection for locally advanced nonmetastatic colon cancer : A nationwide propensity score matched cohort study. I: Colorectal Disease. 2022 ; Bind 24, Nr. 8. s. 954-964.

Bibtex

@article{9cfd99995c87435fa42b7d985db18fd5,
title = "Neoadjuvant chemotherapy in patients undergoing colonic resection for locally advanced nonmetastatic colon cancer: A nationwide propensity score matched cohort study",
abstract = "Aim: Neoadjuvant chemotherapy (NCT) for nonmetastatic colon cancer is not routinely used, and is currently only recommended as a treatment option for a subgroup of patients with T4b colon cancers in clinical guidelines. However, NCT may cause downstaging of the tumour, increase resectability, eradicate micrometastases and thereby improve long-term outcomes for patients with nonmetastatic colon cancer. The aim of this study was to investigate the short-term postoperative outcomes in a nationwide cohort of patients with locally advanced colon cancer (LACC) receiving NCT. Method: Using the Danish Colorectal Cancer Group Database, data were retrieved on patients diagnosed with LACC (defined as clinical T3 with extramural tumour invasion >5 mm or T4) and treated with resection with a curative intent between 2015 and 2019. Propensity score matching (PSM) in a 1:1 ratio was performed to compare short-term surgical and oncological outcomes in patients receiving NCT with patients operated on without receiving NCT. Results: A total of 179 LACC patients were treated with NCT and 1131 were not. After PSM, 145 patients remained in each group. We found no significant differences in any short-term postoperative outcomes between the two groups. We found significant differences in favour of NCT regarding radicality and pathological N category [86% vs. 81% R0 (P = 0.029) and 51% vs. 46% pN0 (P = 0.017), respectively]. Conclusion: Neoadjuvant chemotherapy for LACC does not result in worse short-term postoperative outcomes and may increase the R0 rate as well as node-negative disease. Results on long-term benefits including survival are awaited from several ongoing randomized controlled trials.",
keywords = "colon cancer, nationwide cohort study, neoadjuvant chemotherapy, propensity score matching, short-term outcomes",
author = "Magnus Laursen and Niclas Dohrn and Ismail G{\"o}genur and Klein, {Mads Falk}",
note = "Publisher Copyright: {\textcopyright} 2022 Association of Coloproctology of Great Britain and Ireland.",
year = "2022",
doi = "10.1111/codi.16116",
language = "English",
volume = "24",
pages = "954--964",
journal = "Colorectal Disease",
issn = "1462-8910",
publisher = "Wiley-Blackwell",
number = "8",

}

RIS

TY - JOUR

T1 - Neoadjuvant chemotherapy in patients undergoing colonic resection for locally advanced nonmetastatic colon cancer

T2 - A nationwide propensity score matched cohort study

AU - Laursen, Magnus

AU - Dohrn, Niclas

AU - Gögenur, Ismail

AU - Klein, Mads Falk

N1 - Publisher Copyright: © 2022 Association of Coloproctology of Great Britain and Ireland.

PY - 2022

Y1 - 2022

N2 - Aim: Neoadjuvant chemotherapy (NCT) for nonmetastatic colon cancer is not routinely used, and is currently only recommended as a treatment option for a subgroup of patients with T4b colon cancers in clinical guidelines. However, NCT may cause downstaging of the tumour, increase resectability, eradicate micrometastases and thereby improve long-term outcomes for patients with nonmetastatic colon cancer. The aim of this study was to investigate the short-term postoperative outcomes in a nationwide cohort of patients with locally advanced colon cancer (LACC) receiving NCT. Method: Using the Danish Colorectal Cancer Group Database, data were retrieved on patients diagnosed with LACC (defined as clinical T3 with extramural tumour invasion >5 mm or T4) and treated with resection with a curative intent between 2015 and 2019. Propensity score matching (PSM) in a 1:1 ratio was performed to compare short-term surgical and oncological outcomes in patients receiving NCT with patients operated on without receiving NCT. Results: A total of 179 LACC patients were treated with NCT and 1131 were not. After PSM, 145 patients remained in each group. We found no significant differences in any short-term postoperative outcomes between the two groups. We found significant differences in favour of NCT regarding radicality and pathological N category [86% vs. 81% R0 (P = 0.029) and 51% vs. 46% pN0 (P = 0.017), respectively]. Conclusion: Neoadjuvant chemotherapy for LACC does not result in worse short-term postoperative outcomes and may increase the R0 rate as well as node-negative disease. Results on long-term benefits including survival are awaited from several ongoing randomized controlled trials.

AB - Aim: Neoadjuvant chemotherapy (NCT) for nonmetastatic colon cancer is not routinely used, and is currently only recommended as a treatment option for a subgroup of patients with T4b colon cancers in clinical guidelines. However, NCT may cause downstaging of the tumour, increase resectability, eradicate micrometastases and thereby improve long-term outcomes for patients with nonmetastatic colon cancer. The aim of this study was to investigate the short-term postoperative outcomes in a nationwide cohort of patients with locally advanced colon cancer (LACC) receiving NCT. Method: Using the Danish Colorectal Cancer Group Database, data were retrieved on patients diagnosed with LACC (defined as clinical T3 with extramural tumour invasion >5 mm or T4) and treated with resection with a curative intent between 2015 and 2019. Propensity score matching (PSM) in a 1:1 ratio was performed to compare short-term surgical and oncological outcomes in patients receiving NCT with patients operated on without receiving NCT. Results: A total of 179 LACC patients were treated with NCT and 1131 were not. After PSM, 145 patients remained in each group. We found no significant differences in any short-term postoperative outcomes between the two groups. We found significant differences in favour of NCT regarding radicality and pathological N category [86% vs. 81% R0 (P = 0.029) and 51% vs. 46% pN0 (P = 0.017), respectively]. Conclusion: Neoadjuvant chemotherapy for LACC does not result in worse short-term postoperative outcomes and may increase the R0 rate as well as node-negative disease. Results on long-term benefits including survival are awaited from several ongoing randomized controlled trials.

KW - colon cancer

KW - nationwide cohort study

KW - neoadjuvant chemotherapy

KW - propensity score matching

KW - short-term outcomes

U2 - 10.1111/codi.16116

DO - 10.1111/codi.16116

M3 - Journal article

C2 - 35285992

AN - SCOPUS:85127453227

VL - 24

SP - 954

EP - 964

JO - Colorectal Disease

JF - Colorectal Disease

SN - 1462-8910

IS - 8

ER -

ID: 314065856